This study evaluates neuroimaging biomarkers as predictors of accelerated degeneration and cognitive abnormalities in chronic epilepsy patients. Using advanced positron emission tomography (PET) and magnetic resonance imaging (MRI) to document age-accelerated abnormalities in chronic focal epilepsy, we will compare neuroimaging biomarkers and cognitive measures between epilepsy and control groups. In secondary analyses, we will model the impact of risk factors on neuroimaging and cognitive measures to determine the degree to which they serve to accelerate or protect against brain and cognitive aging.
This project was funded by: start-up funds
The term of this project was: June 2018 to March 2020
The number of subjects scanned during this project was: 50